Trial record 1 of 1 for:
dovacc
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (DOVACC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04742075 |
|
Recruitment Status :
Recruiting
First Posted : February 5, 2021
Last Update Posted : September 8, 2023
|
Sponsor:
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators:
North Eastern German Society of Gynaecological Oncology
Belgian Gynaecological Oncology Group
Hellenic Cooperative Oncology Group
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Information provided by (Responsible Party):
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 15, 2024 |
| Estimated Study Completion Date : | December 15, 2026 |